These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 6343858)

  • 21. Etiology of the so-called "idiopathic scoliosis". Biomechanical explanation of spine deformity. Two groups of development of scoliosis. New rehabilitation treatment; possibility of prophylactics.
    Karski T
    Stud Health Technol Inform; 2002; 91():37-46. PubMed ID: 15457691
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Progressive Duchenne muscular dystrophy: general practice aspects of diagnostic assessment].
    Nussbaum JM; Diller KG; Reitter B
    Monatsschr Kinderheilkd; 1987 Jun; 135(6):320-4. PubMed ID: 3614228
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A method to evaluate contractures effects during the gait of children with Duchenne dystrophy.
    Gaudreault N; Gravel D; Nadeau S; Desjardins P; Brière A
    Clin Orthop Relat Res; 2007 Mar; 456():51-7. PubMed ID: 17195816
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of mazindol on growth hormone levels in patients with Duchenne muscular dystrophy.
    Zatz M; Rapaport D; Vainzof M; Pavanello Rde C; Rocha JM; Betti RT; Otto PA
    Am J Med Genet; 1988 Dec; 31(4):821-33. PubMed ID: 3239574
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Relations between delayed diagnosis and forms of onset in Duchenne muscular dystrophy].
    Alvarez Leal M; Morales Aguilera A; Pérez Zuno JA; Segura Romero S; Quiroz Góngora MC; Paredes García A
    Gac Med Mex; 1994; 130(6):459-64. PubMed ID: 7557061
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Upper extremity functional rating for patients with Duchenne muscular dystrophy.
    Lord JP; Portwood MM; Lieberman JS; Fowler WM; Berck P
    Arch Phys Med Rehabil; 1987 Mar; 68(3):151-4. PubMed ID: 3827555
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative analysis between Duchenne and Becker types muscular dystrophy.
    Ishpekova B; Milanov I; Christova LG; Alexandrov AS
    Electromyogr Clin Neurophysiol; 1999; 39(5):315-8. PubMed ID: 10422002
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical trials of vasoactive and antiserotonin drugs in Duchenne muscular dystrophy.
    Patten BM; Zeller RS
    Ann Clin Res; 1983 Aug; 15(4):164-6. PubMed ID: 6360027
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Double-blind study of the efficacy of an antiserotoninergic drug, pizotifen, in Duchenne's muscular dystrophy].
    Steru D; Paclet JP; Barthelet G; Gailliard G; Piton A; Monchartre E; Roche R; Galli J; Lancrenon S; Fermanian J
    Arch Fr Pediatr; 1987; 44(6):461-5. PubMed ID: 3619586
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Upper vs lower extremity functional loss in neuromuscular disease.
    Lord JP; Portwood MM; Fowler WM; Lieberman JS; Carson R
    Arch Phys Med Rehabil; 1987 Jan; 68(1):8-9. PubMed ID: 3800628
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Database for patients with Duchenne muscular dystrophy].
    Fukunaga H; Ishiduka T; Sato M; Igata A; Nishitani H
    Rinsho Shinkeigaku; 1990 Nov; 30(11):1202-7. PubMed ID: 2085925
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Posterior spinal fusion for scoliosis in duchenne muscular dystrophy diminishes the rate of respiratory decline.
    Velasco MV; Colin AA; Zurakowski D; Darras BT; Shapiro F
    Spine (Phila Pa 1976); 2007 Feb; 32(4):459-65. PubMed ID: 17304138
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Delayed diagnosis of Duchenne muscular dystrophy in Chile].
    de los Angeles Avaria M; Kleinsteuber K; Herrera L; Carvallo P
    Rev Med Chil; 1999 Jan; 127(1):65-70. PubMed ID: 10436681
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nine-year follow-up study of heart rate variability in patients with Duchenne-type progressive muscular dystrophy.
    Yotsukura M; Fujii K; Katayama A; Tomono Y; Ando H; Sakata K; Ishihara T; Ishikawa K
    Am Heart J; 1998 Aug; 136(2):289-96. PubMed ID: 9704692
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospective study of X-linked progressive muscular dystrophy in Campania.
    Nigro G; Comi LI; Limongelli FM; Giugliano MA; Politano L; Petretta V; Passamano L; Stefanelli S
    Muscle Nerve; 1983 May; 6(4):253-62. PubMed ID: 6683357
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical investigation of Duchenne muscular dystrophy. Interesting results in a trial of prednisone.
    Brooke MH; Fenichel GM; Griggs RC; Mendell JR; Moxley RT; Miller JP; Kaiser KK; Florence JM; Pandya S; Signore L
    Arch Neurol; 1987 Aug; 44(8):812-7. PubMed ID: 3632393
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacological strategies for muscular dystrophy.
    Khurana TS; Davies KE
    Nat Rev Drug Discov; 2003 May; 2(5):379-90. PubMed ID: 12750741
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ineffectiveness of allopurinol in Duchenne muscular dystrophy.
    Doriguzzi C; Bertolotto A; Ganzit GP; Mongini T; Palmucci L
    Muscle Nerve; 1981; 4(2):176-8. PubMed ID: 7010155
    [No Abstract]   [Full Text] [Related]  

  • 39. Deletion analysis of Duchenne muscular dystrophy.
    Erdem H; Ayter S; Ozgüç M; Topçu M; Topaloğlu H; Renda Y
    Turk J Pediatr; 1993; 35(1):15-21. PubMed ID: 8236513
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The natural history of Duchenne muscular dystrophy: a caveat for therapeutic trials.
    Brooke MH; Griggs RC; Mendell JR; Fenichel GM; Shumate JB
    Trans Am Neurol Assoc; 1981; 106():195-9. PubMed ID: 7348993
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.